Penumbra (PEN) Asset Writedowns and Impairment (2014 - 2026)
Penumbra's (PEN) quarterly Asset Writedowns and Impairment came in at $1.6 million in Q1 2026, down 34.25% year-on-year from $2.5 million in Q1 2025, and up 138.6% on a QoQ basis from -$4.2 million in Q4 2025.
Penumbra (PEN) Asset Writedowns and Impairment (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Asset Writedowns and Impairment data on file, last reported at $1.6 million in Q1 2026.
- On a quarterly basis, Asset Writedowns and Impairment fell 34.25% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was -$2.6 million, a 103.27% decrease from a year earlier, with the FY2024 full-year figure at $76.9 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at $1.6 million, up from -$4.2 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for PEN reached as high as $76.9 million in Q2 2024 and fell as low as -$5.2 million in Q4 2023.
- Historically, Asset Writedowns and Impairment has averaged $6.9 million across 5 years, with a median of $980000.0 in 2022.
- Across the five-year window, Asset Writedowns and Impairment sank 489.18% in 2023 and surged 594.13% in 2025, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at $1.3 million in 2022, then sank by 489.18% to -$5.2 million in 2023, then soared by 1564.76% to $76.9 million in 2024, then sank by 105.5% to -$4.2 million in 2025, then jumped by 138.6% to $1.6 million in 2026.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $1.6 million in Q1 2026, -$4.2 million in Q4 2025, and $2.5 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.00 Bn | 175.71 Bn | 6.27 Bn |
| 2 | Stryker | 128.69 Bn | 125.81 Bn | 3.81 Bn |
| 3 | Medtronic | 108.82 Bn | 99.60 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.39 Bn | 66.93 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.97 Bn | 44.30 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.29 Bn | 26.00 Bn | 1.98 Bn |
| 7 | Dexcom | 28.21 Bn | 27.09 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.32 Bn | 2.07 Bn |
| 10 | Penumbra | 12.57 Bn | 11.95 Bn | 253.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.63 Mn |
| Mar 31, 2026 | 1.63 Mn |
| Dec 31, 2025 | -4.23 Mn |
| Dec 31, 2025 | -4.23 Mn |
| Mar 31, 2025 | 2.49 Mn |
| Mar 31, 2025 | 2.49 Mn |
| Jun 30, 2024 | 76.90 Mn |
| Jun 30, 2024 | 76.90 Mn |
| Mar 31, 2024 | 358,000.00 |
| Mar 31, 2024 | 358,000.00 |
| Dec 31, 2023 | -5.25 Mn |
| Dec 31, 2023 | -5.25 Mn |
| Mar 31, 2023 | 1.01 Mn |
| Mar 31, 2023 | 1.01 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | 478,000.00 |
| Sep 30, 2022 | 478,000.00 |
| Jun 30, 2022 | 980,000.00 |
| Jun 30, 2022 | 980,000.00 |